高级搜索
李嵘, 刘秀峰, 何泽明, 华海清, 王琳, 陈映霞. 伊立替康联合替加氟持续静脉滴注治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
引用本文: 李嵘, 刘秀峰, 何泽明, 华海清, 王琳, 陈映霞. 伊立替康联合替加氟持续静脉滴注治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
LI Rong, LIU Xiu-feng, HE Ze-ming, HUA Hai-qing, WANG Lin, CHEN Ying-xia. Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020
Citation: LI Rong, LIU Xiu-feng, HE Ze-ming, HUA Hai-qing, WANG Lin, CHEN Ying-xia. Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(12): 1419-1422. DOI: 10.3971/j.issn.1000-8578.2011.12.020

伊立替康联合替加氟持续静脉滴注治疗晚期结直肠癌的临床观察

Preliminary Clinical Observation on Irinotecan Combined with Continuous Infusion of Tegafur in Treating Patients with Advanced Colorectal Carcinoma

  • 摘要: 目的观察国产伊立替康(Irinotecan)联合替加氟(Tegafur)持续静脉滴注治疗晚期结直肠癌的有效性及安全性。方法全组共53例,方案具体用法为:国产伊立替康150 mg/m2~180 mg/m2静脉滴注 d1,替加氟 2000 mg/m2 持续静脉滴注48 h,亚叶酸钙注射液 200 mg/m2静脉滴注d1、d2。2周重复用药。4周期后按照RECIST标准评价近期客观疗效,按照NCI-CTC评价不良反应。结果全组共接受了432周期化疗,每例4~14周期,平均8.2周期。51例可评价疗效,53例可评价不良反应。获得CR 3例(5.9%),PR 11例(21.6%),有效率(RR)为27.5%,疾病控制率(DCR)66.7%。中位疾病进展时间(TTP)6.5月。常见不良反应为血液学毒性(白细胞下降43.4%,Ⅲ度白细胞下降占3.8%)和腹泻(20.8%)。结论伊立替康联合替加氟治疗晚期结直肠癌疗效较好,同时不良反应可耐受、可逆并易于处理,值得临床进一步应用。

     

    Abstract: ObjectiveTo observe the availability and the safety of the therapy using Irinotecan combined with continuous infusion of tegafur in advanced colorectal cancer.MethodA total of 53 patients were given chemotherapy regimen.That's 150 to 180mg per square meter of Irinotecan parenteral solution,i.v.on day 1 and fuorouracil 200 mg/m2 and Tagafur 2000 mg/m2 civ.48h,on day 1 and day 2.Reiterature per 2 w.To evaluate the near future therapeutic effect according to the RECIST standard and to evaluate the toxic reaction according to the NCI-CTC standard 2w later.ResultAll patients had total accepted 432 chemotherapy cycles.There 4 to 14 cycles for one patient and the average was 8.2 cycles for one patient.Fifty-one of the patients′ recent therapentic efficacy could be evaluated,and 53 of the patients′ toxic reaction could be evaluated.The overall response rate (RR) was 27.5%,and the disease control rate (DCR) was 66.7%.Three of these gained clinic completed relief,and 11 of these gained partial relief.The TTP was 6.5 m,the common toxic reaction was Leucopenia 43.4%(3.8% in grade Ⅲ) and diarrhea 20.8% . Conclusion The chemotherapy regimen with a combination of Irinotecan and fuorouracil had indeed better therapeutic effect,moreover the toxic reaction was tolerant,reversible and easy to handle,which shows more potential clinic applications.

     

/

返回文章
返回